- Home
- AIRS vs ABEO Comparison
AIRS vs ABEO Comparison
Compare AIRS & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- ABEO
- Stock Information
- Founded
- AIRS 2012
- ABEO 1974
- Country
- AIRS United States
- ABEO United States
- Employees
- AIRS N/A
- ABEO N/A
- Industry
- AIRS Medical/Nursing Services
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- ABEO Health Care
- Exchange
- AIRS Nasdaq
- ABEO Nasdaq
- Market Cap
- AIRS 166.3M
- ABEO 289.2M
- IPO Year
- AIRS 2021
- ABEO 1980
- Fundamental
- Price
- AIRS $10.50
- ABEO $5.53
- Analyst Decision
- AIRS Hold
- ABEO Strong Buy
- Analyst Count
- AIRS 3
- ABEO 6
- Target Price
- AIRS $3.75
- ABEO $18.17
- AVG Volume (30 Days)
- AIRS 972.2K
- ABEO 994.6K
- Earning Date
- AIRS 11-07-2025
- ABEO 11-13-2025
- Dividend Yield
- AIRS N/A
- ABEO N/A
- EPS Growth
- AIRS N/A
- ABEO N/A
- EPS
- AIRS N/A
- ABEO 0.99
- Revenue
- AIRS $165,109,000.00
- ABEO $400,000.00
- Revenue This Year
- AIRS N/A
- ABEO N/A
- Revenue Next Year
- AIRS $5.14
- ABEO $324.71
- P/E Ratio
- AIRS N/A
- ABEO $5.44
- Revenue Growth
- AIRS N/A
- ABEO N/A
- 52 Week Low
- AIRS $1.53
- ABEO $3.93
- 52 Week High
- AIRS $10.74
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- AIRS 69.33
- ABEO 47.92
- Support Level
- AIRS $8.91
- ABEO $5.21
- Resistance Level
- AIRS $10.71
- ABEO $5.70
- Average True Range (ATR)
- AIRS 0.76
- ABEO 0.26
- MACD
- AIRS 0.13
- ABEO 0.06
- Stochastic Oscillator
- AIRS 90.83
- ABEO 68.81
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.